Erythroderma patient with chronic kidney disease treated with systemic corticosteroids
Keywords:
Corticosteroids, Erythema, ErythrodermaAbstract
Erythroderma is a rare but emergency case because it is a potentially life-threatening condition. It is described as generalized erythema and skin scaling, involving greater than 90% of body surface area. It can be caused by several etiologies, which the most common cause is psoriasis. The pathogenesis depends on the underlying cause. Establishing the definitive diagnosis is still challenging since the histopathology examination is gold standard for erythroderma. But not all healthcare facilities have this examination. Some of them use clinical approach to diagnose. Moreover, erythroderma patients should have comprehensive management, including nutritional assessment, correction of fluid and electrolytes imbalances, treatment to secondary infections, topical therapy, and systemic agents. Targeted therapy can be used after the underlying cause is established, but it is still considered because of cost-effectiveness and the availability. As an alternative, systemic corticosteroids could be given as one of the treatments, although it is still debated for the side effects. We described a case of erythroderma in a 56-year-old male patient with chronic kidney disease. The patient was diagnosed with his medical history, physical examination and laboratory examination. The management of this patient is comprehensive including topical and systemic agents. Patient’s clinical improvement after given topical and systemic corticosteroids.References
Harper-Kirksey K. Erythroderma. Life-Threatening Rashes. 2018;265-77.
Hoxha S, Fida M, Malaj R, Vasili E. Erythroderma: A Manifestation of Cutaneous and Systemic Diseases. EMJ Allergy Immunol.2020.
Cuellar-Barboza A, Ocampo-Candiani J, Herz-Ruelas ME. A Practical Approach to the Diagnosis and Treatment of Adult Erythroderma. Actas Dermosifiliogr (Engl Ed). 2018;109(9):777-90.
Mistry N, Gupta A, Alavi A, Sibbald RG. A review of the diagnosis and management of erythroderma (generalized red skin). Adv Skin Wound Care. 2015;28(5):228-38.
Susanto PM. Erythrodermic pasoriasis adult male patient treated with systemic corticosteroid: a case report. Jurnal Kesehatan Tambusai. 2022;3(1):336-41.
Teran CG, Teran-Escalera CN, Balderrama C. A severe case of erythrodermic psoriasis associated with advanced nail and joint manifestations: a case report. J Med Case Rep. 2010;4:179.
Hu Y, Yin L, Xu J, Yin Z, Renal function of psoriatic patients: erythrodermic psoriasis has more significant hyperuricemia. Biomed Res. 2017;28(6):2515-18.
Okoduwa C, Lambert WC, Schwartz RA, et al. Erythroderma: review of a potentially life-threatening dermatosis. Indian J Dermatol. 2009;54(1):1-6.
Miyashiro D, Sanches JA. Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center. Sci Rep. 2020;10(1):9774.
Andrews G. Maximizing the Diagnostic Potential of Skin Biopsies. Kansas State Veterinary Diagnostic Laboratory. 2015.
Jean L. Bolognia MD. Erythroderma Treatment. Dermatology 4th edition. Elsevier. 2018.
G Madhuri, CH Kallappa, Kumar S. Erythrodermic psoriasis: a case report. Manipal J Pharm Sci. 2019;5(2):71-3.
Cretu S, Salavastru C, Tiplica GS. Treatment of psoriatic erythroderma using systemic corticosteroids: A timeless option? Dermatol Ther.2020;33(6):e14222.
Rao S, Bernshteyn M, Sohal R, et al. The Management of Erythrodermic Psoriasis Complicated by Cyclosporine. Case Rep Dermatol Med. 2020:5215478.
Heinrich M, Cook E, Roach J, Juarez RM, Payne D, Atkins R, Stetson C. Erythrodermic psoriasis secondary to systemic corticosteroids. Proc (Bayl Univ Med Cent). 2019;33(1):113-4.